http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SK-37996-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_74ddb8511ef13df9849d14b840906aaa
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1623
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-145
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
filingDate 1994-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3ec8c8fc83c659bdc3902126a73b78a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06bffbec1b81ba2a033ead9dbef9c5c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e2adcd99725dad18b571e09f8b92803
publicationDate 1997-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber SK-37996-A3
titleOfInvention Process for preparation of solid dispersions, deposits as well as of solid medicinal forms with dihydropyridine type calcium antagonists
abstract There is described a process for the preparation of solid dispersions and deposits with dihydropyridine type calcium antagonists containing as the active substance one or more 1,4-dihydropyridine derivatives such as nitrendipine, nimodipine and lacidipine and as a carrier one or more water-soluble derivatives of mono-, di-, oligo- and polysaccharides, and, if required, also polymer substances, which are swellable in contact with water, selected from polacrilin potassium, sodium starch glycolate and/or cross-linked carboxy methyl cellulose, and anionogenic or non-ionogenic type surfactants selected from sodium lauryl sulfate, poloxamers and/or higher fatty acids polyoxyethylene sorbitan esters, whereat from the dispersion, preferably a solution and/or suspension of active substance(s), and if required one or more water-soluble adjuvants, selected from mono, di and oligosaccharides, and surfactants selected from sodium lauryl sulfate, poloxamers and/or polyoxyethylene sorbitan esters of higher fatty acids with 12 to 18 carbon atoms, in a solvent selected from lower aliphatic alcohols with 1 to 4 carbon atoms, preferably ethanol and 1-propanol and if required in mixture with water, the solvent is removed by spraying of dispersion under the stream of the heat air and if required to the carrier, selected from one or more of the water-soluble mono, di, oligo and polysaccharides and if required the water-swellable polymer substances from the group of disintegrators, and the anionic or nonionic surfactants. Furthermore, there is described a process for the preparation of solid medicinal forms of dihydropyridine type calcium antagonists, whereat the mentioned solid dispersions and (or) deposits are mixed in a suitable manner with disintegrators and lubricant, and if required the other adjuvants such as carriers and binders, and then by such a mixture there are formed preferably tablets and capsules.
priorityDate 1993-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5460341
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559508
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534805
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5793
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415853316
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID154496863
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419501734
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID643460
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421471511
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419585166
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID84571
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535113
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419508054
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453335048
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419474446
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419490943
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID517347
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411174056
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3423265
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419553385
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456171974
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559194
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID104822
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6251
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66666
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID82170
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5462222
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID433322677
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448380735
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419591195
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5311217
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID151263
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559505
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5780
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4497
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419485854
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8778
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4507
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538410
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID702
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1031

Total number of triples: 61.